skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration
  • Close Icon
Pharma Intelligence brings you critical pharmaceutical research studies, featuring new pharmaceutical research developments, and delivers them to you in a timely fashion. Rely on the experienced experts from Pharma Intelligence for essential information and unparalleled insights you can use to inform your own business decisions and strategies.

Don't miss any of the impactful developments to come out of ESMO 2019

Follow all the highlights from this annual meeting of oncology clinicians, researchers, patient advocates, journalists, and members of the pharmaceutical industry with this report extract. Datamonitor Healthcare’s coverage includes:

• Translational cancer science unveiled at ESMO 2019
• Announcements of potentially practice-changing data
• Important developments from the 5-day event

2019_Post-ESMO_Conference_Report_Extract_Cover_Image

PharmAI – Industry Is Smartening Up To Potential Of Artificial Intelligence

Artificial Intelligence (AI) has enormous potential in changing the delivery of health care and improving patient outcomes, with applications in pattern detection, patient monitoring, disease diagnosis and treatment selection. The rationale is that AI can be used to enhance the decisionmaking process, taking into account far more data than are available to physicians via conventional means. The addition of machine learning (ML)algrithms enables the AI to become better over time, increasing the accuracy or timeliness of its recommendations. Recognizing this broad potential, the FDA has recently sought to spur the industry with its discussion paper on regulating Software as a Medical Device (SaMD) products.

Disease overview

Payers have become increasingly aware of the potential cost burden of multiple myeloma treatment over the past five years, due to several factors:

  • The approvals of several high-cost biologics in increasingly early treatment lines
  • Increased patient life expectancies resulting in extended treatment durations
  • The surge in demand for high-cost combination regimens
DHMC_Market_Access_Phase

最新の医薬品業界ニュース

  • HBW Insight : コンシューマーヘルスケア産業のニュース

    CBD News Round-Up: Australia Proposes OTC Pathway, First EU Novel Food Validation, COVID Boost For UK Firm

    cbd-news

    Australia looks at switching CBD as an OTC medicine, CBDepot becomes the first European firm with an EU Novel Food validation and the UK's Vitality CBD gets a boost from the global, coronavirus-driven wellness trend.

    Topic Dietary Supplements Coronavirus

  • HBW Insight : コンシューマーヘルスケア産業のニュース

    IFRA Chair Looks Forward To Post-COVID-19 ‘Revival Of Reason’

    ifra

    IFRA’s new chairman Hans Holger Gliewe says one possible positive outcome of the COVID-19 pandemic could be that consumers go on putting a premium on scientific expertise after months of reliance on health experts’ advice.

    Topic Coronavirus Cosmetics

  • Generics Bulletin: ジェネリック&バイオシミラーニュース

    Celltrion Sets Out Plans To Trial Coronavirus Treatments

    In an exclusive interview with Generics Bulletin, Celltrion Healthcare’s UK commercial director, Matt Eddleston, has set out the firm’s plans to roll out an antibody test and trial two antiviral treatments for COVID-19. Meanwhile, the company’s recently-launched subcutaneous version of biosimilar infliximab, Remsima SC, is helping to free up hospital space in the UK by allowing treatment to be moved out of that setting as the coronavirus pandemic progresses.

    Topic Coronavirus

  • HBW Insight : コンシューマーヘルスケア産業のニュース

    Bayers Supplement Sales Leap By A Third On COVID Boost

    Bayers Supplement Sales Leap By A Third On COVID Boost Cover Image

    Bayer posts double-digit rise in Q1 Consumer Health sales off the back of unprecedented demand for its dietary supplements in the middle of the global coronavrius pandemic. 

    Topic Coronavirus

  • Generics Bulletin: ジェネリック&バイオシミラーニュース

    Biosimilars Conference Coverage

    Biosimilars Conference Coverage

    Industry analysts from Generics Bulletin are bringing you free insights from their comprehensive biosimilars coverage. Obtain critical industry information covering new biosimilars launches, company strategies, and new biosimilars product development.

    Topic biosimilars

  • Generics Bulletin: ジェネリック&バイオシミラーニュース

    Celltrion Will Trial COVID-19 Antiviral From July

    Celltrion has made progress in finding an effective treatment for COVID-19 by identifying 14 antibodies able to neutralize coronavirus. The company aims to eventually roll out mass production of a therapeutic antibody treatment after starting human trials this July.

    Topic Coronavirus vaccines

  • Generics Bulletin: ジェネリック&バイオシミラーニュース

    Australian Bodies Set Out Joint Position On Coronavirus

    Australia’s off-patent industry association, the GBMA, and local brand organization Medicines Australia have set out their plans for collaborating on supplying essential medicines amid the coronavirus pandemic.

  • HBW Insight : コンシューマーヘルスケア産業のニュース

    ‘Insufficient Evidence’ Ibuprofen Worsens COVID-19, Says UK Regulator

    Review by MHRA advisory body finds no issue with ibuprofen use in COVID-19 patients and updates advice to recommend either paracetamol or ibuprofen to treat symptoms.

    Topic Coronavirus

  • Generics Bulletin: ジェネリック&バイオシミラーニュース

    Coronavirus Puts The Brakes On Mylan-Upjohn Merger

    Mylan and Pfizer’s Upjohn were all set to merge into Viatris by midway through this year, subject to certain approvals, but that will now not happen in that timeframe as the global coronavirus pandemic proves an insurmountable barrier to getting the deal over the line.  

    Topic Coronavirus

  • Generics Bulletin: ジェネリック&バイオシミラーニュース

    Australia Relaxes Competition Rules To Facilitate Coronavirus Response

    Australia’s competition regulator, the ACCC, has granted a conditional dispensation to allow generics industry association the GBMA and brand body Medicines Australia to work together to help address the coronavirus pandemic by sharing information on stock, inventory, manufacturing and the supply chain. However, tender pricing will not be among the subjects discussed.

    Topic Coronavirus

  • Generics Bulletin: ジェネリック&バイオシミラーニュース

    Celltrion Makes Progress On Coronavirus Treatment

    Coronavirus_Elbow_pump

    Celltrion has accelerated the development of its antiviral treatment for COVID-19 and aims to launch a rapid self-testing kit that could provide results within 15-20 minutes. The Korean firm also plans to develop a ‘super antibody’ to prepare for potential future pandemic situations.

    Topic Coronavirus

  • HBW Insight : コンシューマーヘルスケア産業のニュース

    The Race Is On To Launch COVID-19 Antibody Home-Test In The UK

    Feature: Public Health England has revealed it is only a week away from approving a COVID-19 antibody test for distribution via Amazon. HBW Insight looks at the race to place the first, government-approved coronavirus home-test on the UK market.

    Topic Coronavirus

  • Biomedtracker: 開発中医薬品をFDA承認確率で評価, Trialtrove: 医療用医薬品の臨床試験情報デ...

    COVID-19 Infographic

    COVID-19 Infographic

    Access the infographic below which explores the number of treatment drugs for COVID-19 currently in clinical trials or in development, events including progress updates, partnerships, regulatory and trial announcements etc, and the number of articles published on COVID-19 as of March 3, 2020. This data has been tracked and reported via Informa Pharma Intelligence’s clinical, regulatory and commercial data and analytics, and news and insight tools including Biomedtracker, Trialtrove, Pharmaprojects, Scrip, Pink Sheet, Medtech Insight, and Generics Bulletin etc.

    Topic Coronavirus

  • Generics Bulletin: ジェネリック&バイオシミラーニュース

    Sandoz, Teva And Mylan Step Up On Hydroxychloroquine

    To meet expected demand in the weeks and months ahead, Novartis' Sandoz has committed to donate up to 130 million doses of generic hydroxychloroquine – a treatment for malaria currently under investigation as a therapy to aid in the COVID-19 pandemic – while Teva and Mylan have also made strides, as the generics industry continues to play its part in tackling the coronavirus outbreak.

    Topic Coronavirus

  • Generics Bulletin: ジェネリック&バイオシミラーニュース

    Preserving Full Capacity Is Key To Global Coronavirus Reponse

    Leaders around the world must do all they can to ensure that medicines manufacturing and the supply chain are operating at full capacity as part of efforts to tackle the coronavirus outbreak, global off-patent industry association the IGBA has urged.

    Topic Coronavirus

Data and analysis products

sitetrove-pharmaintelligence

Sitetrove: 治験責任医師と治験施設情報のデータベース

Sitetrove(サイトトローブ)は、170か国・40万人以上の治験責任医師(PI: Principal Investigator)と235以上の疾患に対応する11万7千か所以上の治験施設に関する情報を収録するデータベースです。治験責任医師と治験施設に関して業界で最も正確で包括的な情報を提供することで、コスト増につながる治験の遅延を最小化し、お客様の臨床試験を成功に導くようサポートします。Sitetroveに登録される治験責任医師は、豊富な臨床経験や治験に関する十分な知識をもっていることをアナリストにより精査されています。

Key benefits:

  • 治験責任医師と治験施設情報のデータベース
  • 疫学ダッシュボードは見やすいマップビュー
  • Ask-the-Analyst機能で情報に基づく意思決定
data-monitor-health-care-pharma intelligence

Datamonitor Healthcare: 医療用医薬品の市場調査レポート

Datamonitor Healthcare(データモニターヘルスケア)では主要な疾患と医薬品をカバーする市場調査レポートを収載し、定期的に更新しています。市場調査レポート1本単位の購入または疾患単位の購読契約による対象の市場調査レポートすべての閲覧が可能です。新医薬品の市場性の評価や研究開発戦略の立案にご利用ください。

Key benefits:

  • 客観的市場調査の力で成長戦略を確かにする
  • 最新市場予測ツールでアンメットニーズ特定
  • Ask-the-Analyst機能で情報に基づく意思決定
pharma intelligence pharma banner

Pharmaprojects: 医薬品開発パイプラインのデータベース

Pharmaprojects(ファーマプロジェクツ)は、医薬品業界で代表的な開発パイプライン(医療用医薬品候補化合物)のデータベースとして、医薬品企業をはじめとする多くのお客様にご利用いただいています。前臨床試験から上市済み医薬品まで、現在開発中の15,000の薬剤を含む68,000以上の開発パイプライン情報を収録しています。さらに、43,000以上の医薬品を網羅した35年間にわたる過去のデータベースにもアクセスできます。グローバル競争が激しくなる中、競合分析や研究開発戦略の策定に威力を発揮するデータベースです。

Key benefits:

  • 医療用医薬品の研究・開発パイプライン情報
  • 35年間にわたる過去のヒストリカルデータも
  • Ask-the-Analyst機能で情報に基づく意思決定

お問い合わせ&レポートストア

専任スタッフによるデモンストレーションを兼ねたサービスの詳しいご説明、または無料トライアルを常時受け付けています。ご希望の場合は下記のフォームよりお気軽にお申し込みください。

*一部のサービスでは無料トライアルをご利用になれません。

ご質問等ございましたらお気軽にご連絡下さい。

日本(平日:9時~18時)
電話:+81 (0)3 6273 4260
Email:inquiry.jp@informa.com

オンラインショップのレポートストアでは、医療用医薬品の市場調査・分析レポートを常時1000本以上販売しています。レポート1本単位で購入でき、オンラインでご提供いたします。

お探しの情報が見つからない場合はお問い合わせ先までお気軽にご連絡ください。